Thumbnail

High Lp(a) levels increase risk of repeat cardiovascular events—LDL drugs may help

Researchers evaluated data from more than 273,000 patients with a history of ASCVD, noting that higher Lp(a) levels are consistently linked to worse cardiovascular outcomes.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Answering key follow-up questions after the FDA approved TAVR in asymptomatic patients

The approval of certain TAVR valves to be used in asymptomatic patients is expected to make a significant impact on patient care going forward. 

Stenting ‘an important treatment option’ for PCI patients with complete blockages

The study's lead author emphasized that stenting during CTO PCI procedures "should be considered safe and effective in the long term."

HeartMate 3 LVAD abbott

Smaller LV dimensions may increase risk of death for HeartMate 3 LVAD patients

Researchers tracked short- and long-term data from nearly 2,000 patients, presenting their findings in JACC: Heart Failure

Cardiologist heart

World’s first leadless LBBAP procedures linked to ‘promising’ outcomes

Cardiologists are turning to leadless pacemakers more and more for cardiac pacing, but those devices have not previously been able to perform LBBAP. This new analysis includes new data on the world’s very first leadless LBBAP procedures. 

tirzepatide injections Zepbound Eli Lilly

Tirzepatide bests semaglutide in patients with type 2 diabetes, kidney disease and heart failure

Researchers examined data from more than 9,000 patients, sharing their findings at SCAI 2025.

Srihari S. Naidu, MD, FACC, FAHA, MSCAI, assumed the role of president of the Society for Cardiovascular Angiography and Interventions (SCAI) May 3 during the society's annual meeting. He outlined his ambitious plans to take SCAI in some new directions. #SCAI #SCAI2025

New SCAI president lists advocacy, cardiogenic shock among his top priorities

Srihari Naidu, MD, spoke to Cardiovascular Business about his plan to take SCAI in some bold new directions.

cannabis use disorder marijuana joint weed smoking

Consistent cannabis use linked to multiple cardiovascular risks for heart failure patients

Cannabis use can be especially harmful for heart failure patients, according to new data presented at SCAI 2025.